- Email: [email protected]
5122453 Method for discriminating surface stained lymphocytes
xvi
New Patents
detectable antigen therefrom involves the use of a protease. In particular, the antigen can be effectively extracted from a biological specimen which contains whole blood or mucous using a protease. The extracted antigen can be effectively detected in an immunoassay involving antibodies directed to the antigen. The protease is novel to the process and is obtained from Bacillus subtilisin.
5122453 METHOD FOR DISCRIMINATING SURFACE STAINED LYMPHOCYTES Grace E Martin, Robert J Kanter, Young Kim, Leonard Ornstein, Hudson R Ansley assigned to Technicon Instruments Corporation A flow cytometry method for reproducibly detecting and counting a lymphocyte population of interest in a leukocyte suspension or whole blood sample in which the red cells are subsequently lysed. The suspension (or sample) is combined with a reagent comprising a primary antibody, either native, carrying an attached enzyme or biotin or other label, and a fixative reagent, in either order. Where the enzyme is not attached, an enzyme is coupled specifically to the primary antibody. The fixed suspension is reacted with a color-producing enzymecytochemical reagent. The suspension, now including stained and unstained fixed cells, is passed through a flow cytometer and the cells are characterized and counted on the basis of their light-scattering and light-absorbing properties.
5122468 HUT-78 CELL LINES INFECTED WITH HTLV-III WHICH SECRETE GP160 Mangalasseril G Sarngadharan, Vaniambadi S Kalyanaraman assigned to Akzo N V Human Immunodeficiency Virus (HIV) glycoprotein gp 160 is produced in its native form using a clone of HUT78 cells chronically infected with HTLV-III451, known as 6D5451, and grown in serum-free medium, gpl60 is also produced in its native form using a clone of 6D5451 that contains no HTLV-III virus.
5124147 METHOD FOR THE TREATMENT OF ENDOTOXIC SHOCK IN A MAMMAL Alla Wissner, Suresh S Kerwar, Constance Kohler assigned to American Cyanamid Company The invention is a method of treating endotoxic shock in a mammal which comprises administering to the mammal a therapeutically effective amount of an antagonist to Platelet Activating Factor in combination with a therapeutically effective amount of one or more monoclonal or polyclonal antibodies directed toward either Tumor Necrosis Factor alpha, Interleukin-1 beta, Gamma Interferon, or bacterial cell wall lipopolysaccharides.
5124148 METHOD FOR TREATING VIRAL DISEASES WITH ATTENUATED VIRUS Laszlo K Csatary, Richard J Massey assigned to United Cancer Research Institute A method for treating human disease of viral etiology which employs the administration of a pharmaceutically effective amount of a live attenuated virus. Avian paramyxovirus is the virus preferred for use in live attenuated vaccine form, although other viruses of human and nonhuman origin have also been shown to be effective. The administration of a pharmaceutically effective amount of avian paramyxovirus and avian rotavirus vacciine has been shown to be efficacious in the treatment of Herpes virus infections, hepatitis-A, some cancers, aphthous stomatitis, acquired immune deficiency syndrome (AIDS) and polyarteritis nodosa.
5124153 THERAPEUTIC COMPOSITIONS AGAINST STREPTOCOCCAL INFECTIONS, TRANSFORMED HOSTS, METHODS OF IMMUNIZATION AND GENETICALLY ENGINEERED PRODUCTS Edwin H Beachey, Thomas P Poirier, Michael A Kehoe assigned to University of Tennessee Research Corp
New Patents
detectable antigen therefrom involves the use of a protease. In particular, the antigen can be effectively extracted from a biological specimen which contains whole blood or mucous using a protease. The extracted antigen can be effectively detected in an immunoassay involving antibodies directed to the antigen. The protease is novel to the process and is obtained from Bacillus subtilisin.
5122453 METHOD FOR DISCRIMINATING SURFACE STAINED LYMPHOCYTES Grace E Martin, Robert J Kanter, Young Kim, Leonard Ornstein, Hudson R Ansley assigned to Technicon Instruments Corporation A flow cytometry method for reproducibly detecting and counting a lymphocyte population of interest in a leukocyte suspension or whole blood sample in which the red cells are subsequently lysed. The suspension (or sample) is combined with a reagent comprising a primary antibody, either native, carrying an attached enzyme or biotin or other label, and a fixative reagent, in either order. Where the enzyme is not attached, an enzyme is coupled specifically to the primary antibody. The fixed suspension is reacted with a color-producing enzymecytochemical reagent. The suspension, now including stained and unstained fixed cells, is passed through a flow cytometer and the cells are characterized and counted on the basis of their light-scattering and light-absorbing properties.
5122468 HUT-78 CELL LINES INFECTED WITH HTLV-III WHICH SECRETE GP160 Mangalasseril G Sarngadharan, Vaniambadi S Kalyanaraman assigned to Akzo N V Human Immunodeficiency Virus (HIV) glycoprotein gp 160 is produced in its native form using a clone of HUT78 cells chronically infected with HTLV-III451, known as 6D5451, and grown in serum-free medium, gpl60 is also produced in its native form using a clone of 6D5451 that contains no HTLV-III virus.
5124147 METHOD FOR THE TREATMENT OF ENDOTOXIC SHOCK IN A MAMMAL Alla Wissner, Suresh S Kerwar, Constance Kohler assigned to American Cyanamid Company The invention is a method of treating endotoxic shock in a mammal which comprises administering to the mammal a therapeutically effective amount of an antagonist to Platelet Activating Factor in combination with a therapeutically effective amount of one or more monoclonal or polyclonal antibodies directed toward either Tumor Necrosis Factor alpha, Interleukin-1 beta, Gamma Interferon, or bacterial cell wall lipopolysaccharides.
5124148 METHOD FOR TREATING VIRAL DISEASES WITH ATTENUATED VIRUS Laszlo K Csatary, Richard J Massey assigned to United Cancer Research Institute A method for treating human disease of viral etiology which employs the administration of a pharmaceutically effective amount of a live attenuated virus. Avian paramyxovirus is the virus preferred for use in live attenuated vaccine form, although other viruses of human and nonhuman origin have also been shown to be effective. The administration of a pharmaceutically effective amount of avian paramyxovirus and avian rotavirus vacciine has been shown to be efficacious in the treatment of Herpes virus infections, hepatitis-A, some cancers, aphthous stomatitis, acquired immune deficiency syndrome (AIDS) and polyarteritis nodosa.
5124153 THERAPEUTIC COMPOSITIONS AGAINST STREPTOCOCCAL INFECTIONS, TRANSFORMED HOSTS, METHODS OF IMMUNIZATION AND GENETICALLY ENGINEERED PRODUCTS Edwin H Beachey, Thomas P Poirier, Michael A Kehoe assigned to University of Tennessee Research Corp